Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) EPS (Basic): 2020-2024

Historic EPS (Basic) for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$3.68.

  • SAB Biotherapeutics' EPS (Basic) rose 144.64% to $0.50 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 62.22%. This contributed to the annual value of -$3.68 for FY2024, which is 51.83% up from last year.
  • SAB Biotherapeutics' EPS (Basic) amounted to -$3.68 in FY2024, which was up 51.83% from -$7.64 recorded in FY2023.
  • Over the past 5 years, SAB Biotherapeutics' EPS (Basic) peaked at $0.79 during FY2020, and registered a low of -$7.64 during FY2023.
  • Its 3-year average for EPS (Basic) is -$3.92, with a median of -$3.68 in 2024.
  • Per our database at Business Quant, SAB Biotherapeutics' EPS (Basic) tumbled by 1,676.74% in 2023 and then spiked by 51.83% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' EPS (Basic) (Yearly) stood at $0.79 in 2020, then slumped by 179.75% to -$0.63 in 2021, then spiked by 31.75% to -$0.43 in 2022, then crashed by 1,676.74% to -$7.64 in 2023, then spiked by 51.83% to -$3.68 in 2024.